^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TTX-080

    i
    Other names: TTX-080, TTX 080, TTX080
    Associations

    News

    Trials
    Company:
    Tizona Therap
    Drug class:
    HLA G inhibitor
    Related drugs:
    Associations

    News

    Trials
    16d
    The non-classical immune checkpoint HLA-G: a regulatory master switch governing tolerance, evasion, and translational frontiers. (PubMed, Front Oncol)
    Targeting the HLA-G/ILT axis is a promising therapeutic strategy, with clinical trials underway using anti-HLA-G antibodies (e.g., TTX-080) and anti-LILRB1 antibodies (e.g., BND-22), often combined with PD-1/PD-L1 inhibitors. Additionally, HLA-G agonists or engineered cells are being explored for inducing tolerance in autoimmune diseases and transplantation.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HLA-G (Major Histocompatibility Complex, Class I, G) • LILRB1 (Leukocyte Immunoglobulin Like Receptor B1)
    |
    TTX-080
    over1year
    TTX-080-001: TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1, N=240, Recruiting, Tizona Therapeutics, Inc | Active, not recruiting --> Recruiting | Trial primary completion date: Jun 2024 --> Jun 2027
    Enrollment open • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • TTX-080
    over1year
    TTX-080-001: TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1, N=240, Active, not recruiting, Tizona Therapeutics, Inc | Trial completion date: Jun 2024 --> Jun 2027 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • TTX-080
    2years
    TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1, N=240, Active, not recruiting, Tizona Therapeutics, Inc | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • TTX-080
    over2years
    TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers (clinicaltrials.gov)
    P1a/1b, N=240, Active, not recruiting, Tizona Therapeutics, Inc | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2023 --> Dec 2023
    Enrollment closed • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • TTX-080